Social Media Ideas for Ars Pharmaceuticals

Argenx

Argenx Anonymous (not verified) Sun, 06/07/2026 - 17:48 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Argenx

Argenx Anonymous (not verified) Sat, 05/30/2026 - 14:41 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

Here’s Why Armata Pharmaceuticals Inc. (ARMP) is a High Growth Micro-Cap Stock to Buy?

<![CDATA[Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics]]>

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted i...

Newport pharmacy says aspirin shortage is putting patients and staff under pressure

Aspirin, commonly used for pain relief and heart health, is in particularly short supply, according to Malpas Brook Pharmacy.

Apogee Therapeutics: Targeting Atopic Dermatitis

ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership

The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were stru...

FDA approves AstraZeneca’s new kind of hypertension drug

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in an...

<![CDATA[Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Col...

<![CDATA[AbbVie to Acquire Apogee Therapeutics in $10 Billion Deal]]>

<![CDATA[U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report ]]>

Advancing corticosteroids and hormonal therapies for supply and scale

Today we’re diving into the world of corticosteroids and hormonal therapies, essential APIs that treat everything from asthma and autoimmune diseases to diabetes and endocrine diso...

<![CDATA[Ascidian and Eli Lilly Enter $1.9 Billion Global Research Collaboration to Develop RNA Exon Editors]]>

FDA Approves AstraZeneca Drug With New Approach to Lowering High Blood Pressure

AstraZeneca’s Baxfendy is the first FDA-approved drug in a new class of medicines called aldosterone synthase inhibitors. The new mechanism of action is important for patients and...

<![CDATA[AstraZeneca Shares Drop Following Wainua’s Failed Heart Disease Trial ]]>

<![CDATA[Insilico Medicine Enters $2.5 Billion Alliance with Bora Pharmaceuticals ]]>

Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde. 

AbbVie’s $11B Apogee Acquisition Brings an Eczema Drug With an Edge

Apogee Therapeutics brings AbbVie a long-acting antibody ready for Phase 3 testing in atopic dermatitis, also called eczema. This therapy’s pipeline in a product potential includes...

Apogee eczema drugs gets Blackstone backing, heads to Phase 3

The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.

Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

AstraZeneca's Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with oth...

<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Ther...

<![CDATA[Pharmaceutical Executive Daily: Alnylam Pharmaceuticals and Inceptive Nucleics Announce 3 Year Strategic Col...